# Cumberland Pharmaceuticals Inc: overview CPIX · Nasdaq · CIK 1087294 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cpix.md) · [Financials](/companies/cpix/financials.md) · [Filings](/companies/cpix/filings.md) · [Insiders](/companies/cpix/insiders.md) Latest reported revenue: [$8.8m](/filings/0001087294-26-000062.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001087294-26-000062). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.1](/filings/0001087294-26-000020.md) | [10.4](/filings/0001087294-26-000020.md) | [11.7](/filings/0001087294-26-000049.md) | [10.8](/filings/0001087294-26-000062.md) | [8.3](/filings/0001087294-26-000020.md) | [13.7](/filings/0001087294-26-000020.md) | [9.1](/filings/0001087294-26-000049.md) | [8.8](/filings/0001087294-26-000062.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(18.6%)](/filings/0001087294-26-000020.md) | [(17.7%)](/filings/0001087294-26-000020.md) | [11.0%](/filings/0001087294-26-000049.md) | [(28.8%)](/filings/0001087294-26-000062.md) | [(23.7%)](/filings/0001087294-26-000020.md) | [(10.0%)](/filings/0001087294-26-000020.md) | [(34.3%)](/filings/0001087294-26-000049.md) | [(35.9%)](/filings/0001087294-26-000062.md) | | Net margin | % | [(17.0%)](/filings/0001087294-26-000020.md) | [(18.2%)](/filings/0001087294-26-000020.md) | [10.7%](/filings/0001087294-26-000049.md) | [(6.8%)](/filings/0001087294-26-000062.md) | [(23.4%)](/filings/0001087294-26-000020.md) | [(10.3%)](/filings/0001087294-26-000020.md) | [(36.0%)](/filings/0001087294-26-000049.md) | [(48.6%)](/filings/0001087294-26-000062.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001087294-25-000020.md) | [(0.14)](/filings/0001628280-25-011366.md) | [0.08](/filings/0001087294-26-000049.md) | [(0.05)](/filings/0001087294-26-000062.md) | [(0.13)](/filings/0001087294-26-000020.md) | [(0.09)](/filings/0001087294-26-000020.md) | [(0.22)](/filings/0001087294-26-000049.md) | [(0.29)](/filings/0001087294-26-000062.md) | | Free cash flow | $m | [0.5 d](/filings/0001087294-25-000020.md) | [1.9 d](/filings/0001087294-26-000020.md) | [3.9](/filings/0001087294-26-000049.md) | [0.8 d](/filings/0001087294-26-000062.md) | [0.2 d](/filings/0001087294-25-000020.md) | [0.0 d](/filings/0001087294-26-000020.md) | [0.4](/filings/0001087294-26-000049.md) | [0.1 d](/filings/0001087294-26-000062.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [35.0](/filings/0001628280-23-007727.md) | [42.0](/filings/0001628280-24-010725.md) | [39.6](/filings/0001628280-25-011366.md) | [37.9](/filings/0001087294-26-000020.md) | [44.5](/filings/0001087294-26-000020.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(21.9%)](/filings/0001628280-23-007727.md) | [(13.6%)](/filings/0001628280-24-010725.md) | [(24.2%)](/filings/0001628280-25-011366.md) | [(17.0%)](/filings/0001087294-26-000020.md) | [(6.3%)](/filings/0001087294-26-000020.md) | | Net margin | % | [(10.0%)](/filings/0001628280-23-007727.md) | [(13.3%)](/filings/0001628280-24-010725.md) | [(15.9%)](/filings/0001628280-25-011366.md) | [(17.1%)](/filings/0001087294-26-000020.md) | [(6.4%)](/filings/0001087294-26-000020.md) | | Diluted EPS | $ per share | [(0.24)](/filings/0001628280-23-007727.md) | [(0.38)](/filings/0001628280-24-010725.md) | [(0.44)](/filings/0001628280-25-011366.md) | [(0.46)](/filings/0001087294-26-000020.md) | [(0.19)](/filings/0001087294-26-000020.md) | | Free cash flow | $m | [6.2](/filings/0001628280-23-007727.md) | [8.4](/filings/0001628280-24-010725.md) | [5.8](/filings/0001628280-25-011366.md) | [(0.7)](/filings/0001087294-26-000020.md) | [4.8](/filings/0001087294-26-000020.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cpix/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $3.3m | 503,153 | | Reduced −50,000 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.1m | 478,263 | | Added +7,567 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.5m | 379,478 | | Added +17,719 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $1.5m | 233,305 | | Reduced −43,054 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.3m | 200,700 | Call | Added +144,000 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $729.3k | 112,544 | | Reduced −15,150 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $702.6k | 108,413 | | Reduced −5,880 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $628.4k | 96,982 | | Reduced −99,996 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $516.5k | 79,700 | Put | Added +62,900 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $475.6k | 73,391 | | Added +56,748 | ## Recent filings [All 997 filings](/companies/cpix/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 17:01 ET | [8-K](/filings/0001087294-26-000070.md) | 8.01 Other events | 0001087294-26-000070 | | 2026-09-11 | 16:51 ET | [8-K/A](/filings/0001087294-26-000068.md) | 5.07 Shareholder vote results | 0001087294-26-000068 | | 2026-08-28 | 17:08 ET | [8-K](/filings/0001087294-26-000064.md) | 7.01 Regulation FD disclosure | 0001087294-26-000064 | | 2026-08-07 | 17:12 ET | [10-Q](/filings/0001087294-26-000062.md) | Quarterly report, period 2026-06-30 | 0001087294-26-000062 | | 2026-08-04 | 17:20 ET | [8-K](/filings/0001087294-26-000058.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001087294-26-000058 | | 2026-07-13 | 17:28 ET | [8-K](/filings/0001087294-26-000055.md) | 8.01 Other events | 0001087294-26-000055 | | 2026-07-01 | 16:15 ET | [8-K](/filings/0001104659-26-079871.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-079871 | | 2026-06-25 | 17:00 ET | [8-K](/filings/0001087294-26-000053.md) | 5.07 Shareholder vote results | 0001087294-26-000053 | | 2026-05-08 | 17:02 ET | [10-Q](/filings/0001087294-26-000049.md) | Quarterly report, period 2026-03-31 | 0001087294-26-000049 | | 2026-05-05 | 17:07 ET | [8-K](/filings/0001087294-26-000046.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001087294-26-000046 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001087294-26-000020.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/df4e2866-db65-47b2-8aab-4c54d80c39d9) ## About the filer - CIK: 1087294 - Tickers: CPIX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: TN - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:41 ET. No prices; not investment advice.